BMS 919373

Drug Profile

BMS 919373

Alternative Names: BMS-919373; Ikur inhibitor - Bristol-Myers Squibb

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antiarrhythmics; Pyridines; Quinazolines; Small molecules; Sulfonamides
  • Mechanism of Action Kv1.5 potassium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute coronary syndromes; Atrial fibrillation; Paroxysmal atrial fibrillation

Most Recent Events

  • 07 Mar 2017 Chemical structure information added
  • 14 Feb 2017 Bristol-Myers Squibb terminates a phase I trial in Atrial fibrillation in USA and Canada due to insufficient enrolment(NCT02153437)
  • 01 Jan 2017 Discontinued - Phase-I for Acute coronary syndromes (In volunteers) in USA (PO, Suspension)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top